Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen.
He says feedback from the dose escalation study confirmed Clevegen has good tolerability across all dosing levels tested and that, surprisingly, lower doses could potentially induce a stronger immune response.
''I feel extremely confident at the moment absolutely'', Jalkanen says.
''The clinical benefits have already been seen which we didn't anticipate at this early stage because it was more about dose escalation.
''2020 will be a very interesting year for us''.